Sanofi Grows Revenue by 6.8% in Fourth Quarter Boosted by Dupixent
Sanofi (NASDAQ: SNY) saw sales increase 6.8% in the fourth quarter to €9.608 billion ($10.55 billion). Some of the increase was due to a stronger Euro; at constant exchange rates, sales were up a more modest 4.7% year over year.
On the bottom line, Sanofi lost €10 million as there was an impairment charge associated with its hemophilia treatment Eloctate that's struggling in the U.S. due to added competition. But on an adjusted basis, which Sanofi calls its "business net income," the French pharmaceutical company made €1.684 billion, up 18.4% year over year.
The results drove shares of Sanofi up 4.7% on Thursday.
Source Fool.com
